Advik Laboratories Ltd Stock Analysis

BSE: 531686 | NSE: | Pharmaceuticals & Drugs | Small Cap

BSE Share Price 19-Sep-2022 18:01
1.74 0.00 (0.00%)

DeciZen - Make an Informed Decision on Advik Lab

M-Cap below 100cr DeciZen not available

Advik Lab Price Chart

P/E Ratio (SA) :
Market Cap :
3.3 Cr.
52-wk low :
52-wk high :
Bole Toh?

1. Is Advik Laboratories Ltd a good quality company?

Data is not available for this company.

2. Is Advik Laboratories Ltd undervalued or overvalued?

The key valuation ratios of Advik Laboratories Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is Advik Laboratories Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Advik Laboratories Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Advik Lab:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.

Value Creation

Value Creation Index Colour Code Guide

ROCE % 3.2%6.3%4.9%0.3%-4.3%-33.7%-4.8%-7.5%-7.6%-37.2%-
Value Creation Index -0.8-0.6-0.7-1.0-1.3-3.4-1.4-1.5-1.5-3.7-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 19.933.930.312.
YoY Gr. Rt. %-70.5%-10.6%-59.6%-89%110.4%44%-79.7%-100%NA-
Adj EPS 00.50.3-0.5-0.6-3.9-0.5-0.7-0.6-2.4-0
YoY Gr. Rt. %-NA-41.5%-245.2%NANANANANANA-
BVPS (₹) 11.51211.610.
Adj Net Profit 00.50.5-0.7-1.2-7.4-0.9-1.3-1.2-4.50
Cash Flow from Ops. -1.604.
Debt/CF from Ops. -7.1577.


CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales -100%-100%-100%NA
BVPS -17.3-26.9-28.4-52.7
Share Price -10.6% -19% 29% 43.8%

Key Financial Parameters

Performance Ratio Colour Code Guide

Return on Equity % 04.63-3.4-6.2-48.3-7.7-12.3-13-73.7-1.5
Op. Profit Mgn %
Net Profit Mgn % 01.51.5-5.5-87.9-259.8-21.1-150.5-26692.70-191.1
Debt to Equity
Working Cap Days 2421702255324,1131,3006212,6114,39,26700
Cash Conv. Cycle 1581221363363,2091,0174131,6512,62,89000

Recent Performance Summary

No data to display

Return on Equity is Poor

Sales growth has been subdued in last 3 years 0.00%

Debt to equity has increased versus last 3 years average to 1.45

Sales growth is not so good in last 4 quarters at 0.00%

Latest Financials - Advik Laboratories Ltd.

Standalone Consolidated
TTM EPS (₹) -0 -
TTM Sales (₹ Cr.) 0 -
BVPS (₹.) 1.9 -
Reserves (₹ Cr.) -16 -
P/BV 0.92 -
PE 0.00 -
From the Market
52 Week Low / High (₹) 1.21 / 1.74
All Time Low / High (₹) 0.32 / 53.25
Market Cap (₹ Cr.) 3.3
Equity (₹ Cr.) 19.1
Face Value (₹) 10
Industry PE 37.9

Management X-Ray of Advik Lab :

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *71.1671.1671.1671.1616.0416.0416.0416.0416.0416.04
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Advik Lab

Adj EPS (Rs.)
Sales (Cr.)
ROE (%)
ROCE (%)


About Advik Laboratories Ltd

Advik Laboratories has been set up by V K Jain, a qualified production chemist with over 20 years experience in pharmaceutical products.

Advik Laboratories was established in the 1994. It is WHO-GMP certified company that has been set up from the ground level with the avowed objective of achieving USFDA standards of quality.

The company has a technical collaboration with PFC Pharma Focus of Switzerland. It enjoys leadership status at various fronts such as high product quality, a growing range of products, state of the art manufacturing process, competitive pricing and customer service. In addition the company exports a wide range of drugs to the Middle East, South America and Africa.

The product range includes ethical, generic drugs and over the counter drugs (OTC) in various formulations.

With over 60,000 square feet of built-up area, ample developed open space around it, a state-of-the-art manufacturing facility, the ground floor has provisions for the production and in-process control section for the manufacturing of steroidal & non-steroidal formulations, change room for gents & ladies and stores for raw & packing materials. The first floor has provision for the production and in-process control section for the manufacturing of ampicillin and non-ampicillin capsules and dry syrup preparations. The second floor has provision for quality control and about 12000 sq ft area is presently being reserved for the manufacture of injectables & ointments in the second phase.

Advik Laboratories provides pharmaceutical formulations that match the international standards of quality. The facility manufactures a wide range of pharmaceuticals formulations in tablets, capsules and dry syrups.

Products - Under Ethical products, the company manufactures Wibatol, Wibatol-O, Robial, Twosum, Majispa, Arfa Gel, Stibomin and Chewfe-C.

Under generic products, the company manufactures drugs catering segment such as antibacterials, antiallergics, antifungals, analgesic, antipyretic and anti-inflammatory, anti-hypertensives, anthelminthics, anti-malarials, corticosteroids, erectile dysfunction, gastrointestinal agents and sedatives.

Award - Advik Laboratories has received the prestigious Udyog Patra Award from the Government of India in 1999.

Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now